Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Curr Pharm Des. 2013;19(10):1880–1897. doi: 10.2174/1381612811319100011

Table 3.

Anti-HIV-1IIIB activity of 4′-carbon-substituted stavudine 76-78a

Compd IC50 (μM)a IC50 (μM)b
76 > 100 > 100
77 > 100 > 100
78 (4′-ethynylstavudine) 0.20 > 100
stavudine 2.8 100
a

Data taken from ref. 33.

b

Inhibitory concentration required to achieve 50% protection of MT-2 cells against the cytopathic effect of HIV-1 IIIB.

c

Cytotoxic concentration required to reduce the viability of mock-infected MT-2 cells by 50%.